Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
Psychopharmacology
|
January 1, 1983
Functional supersensitivity to adrenergic agonists in the rat after DSP-4, a selective noradrenergic neurotoxin
D J Dooley, E Mogilnicka, A Delini-Stula, et al.
International Journal of Psychiatry in Clinical Practice
|
June 13, 2014
Assessment of sexual dysfunction in depressed patients and reporting attitudes in routine daily practice: Results of the postmarketing observational studies with moclobemide, a reversible MAO-A inhibitor
M Philipp, A Delini-Stula, D Baier, et al.
Pharmacopsychiatry
|
May 20, 1999
Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor--results of the drug utilization observation studies
A Delini-Stula, D Baier, R Kohnen, et al.
Advances in Biochemical Psychopharmacology
|
January 1, 1982
Stereospecificity of behavioural and biochemical responses to oxaprotiline--a new antidepressant
A Delini-Stula, K Hauser, P Baumann, et al.
International Clinical Psychopharmacology
|
July 1, 1987
First clinical experience with ifoxetine, a new 5-HT reuptake blocker with particular emphasis on the side-effect profile of the 5-HT-uptake inhibiting drugs
A Delini-Stula, R Fischbach, J M Gauthier, et al.
Revue Medicale Suisse
|
March 16, 2007
[Psychiatry]
J M Aubry, A Delini-Stula, N Gervasoni, et al.
Modern Problems of Pharmacopsychiatry
|
January 1, 1983
Characterization of a new, short-acting and specific inhibitor of type A monoamine oxidase
P C Waldmeier, P A Baumann, A Delini-Stula, et al.
Arzneimittel-Forschung
|
January 1, 1984
Sulfonyliminoimidazolidines, a new class of oral hypoglycemic agents. 4. Toxicity and general pharmacology of 1-[p-[2-(crotonylamino)-ethyl]-phenylsulfonyl]-3-cyclohexy l-2-imino- imidazolidine (CGP 11 112)
F Märki, O Büch, A Delini-Stula, et al.
Arzneimittel-Forschung
|
December 1, 1986
Behavioral effects and general pharmacology of 4-(5-chloro-benzofuranyl-2)-1-methylpiperidine HC1, an antidepressant inhibiting both monoamine oxidase A and 5-hydroxytryptamine uptake
R Ortmann, E Radeke, O Buech, et al.
Pharmacopsychiatry
|
November 1, 1988
Non-response to antidepressants: risk factors and therapeutic possibilities
H J Möller, W Kissling, P Baumann, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
Psychopharmacology
|
January 1, 1983
Functional supersensitivity to adrenergic agonists in the rat after DSP-4, a selective noradrenergic neurotoxin
D J Dooley, E Mogilnicka, A Delini-Stula, et al.
International Journal of Psychiatry in Clinical Practice
|
June 13, 2014
Assessment of sexual dysfunction in depressed patients and reporting attitudes in routine daily practice: Results of the postmarketing observational studies with moclobemide, a reversible MAO-A inhibitor
M Philipp, A Delini-Stula, D Baier, et al.
Pharmacopsychiatry
|
May 20, 1999
Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor--results of the drug utilization observation studies
A Delini-Stula, D Baier, R Kohnen, et al.
Advances in Biochemical Psychopharmacology
|
January 1, 1982
Stereospecificity of behavioural and biochemical responses to oxaprotiline--a new antidepressant
A Delini-Stula, K Hauser, P Baumann, et al.
International Clinical Psychopharmacology
|
July 1, 1987
First clinical experience with ifoxetine, a new 5-HT reuptake blocker with particular emphasis on the side-effect profile of the 5-HT-uptake inhibiting drugs
A Delini-Stula, R Fischbach, J M Gauthier, et al.
Revue Medicale Suisse
|
March 16, 2007
[Psychiatry]
J M Aubry, A Delini-Stula, N Gervasoni, et al.
Modern Problems of Pharmacopsychiatry
|
January 1, 1983
Characterization of a new, short-acting and specific inhibitor of type A monoamine oxidase
P C Waldmeier, P A Baumann, A Delini-Stula, et al.
Arzneimittel-Forschung
|
January 1, 1984
Sulfonyliminoimidazolidines, a new class of oral hypoglycemic agents. 4. Toxicity and general pharmacology of 1-[p-[2-(crotonylamino)-ethyl]-phenylsulfonyl]-3-cyclohexy l-2-imino- imidazolidine (CGP 11 112)
F Märki, O Büch, A Delini-Stula, et al.
Arzneimittel-Forschung
|
December 1, 1986
Behavioral effects and general pharmacology of 4-(5-chloro-benzofuranyl-2)-1-methylpiperidine HC1, an antidepressant inhibiting both monoamine oxidase A and 5-hydroxytryptamine uptake
R Ortmann, E Radeke, O Buech, et al.
Pharmacopsychiatry
|
November 1, 1988
Non-response to antidepressants: risk factors and therapeutic possibilities
H J Möller, W Kissling, P Baumann, et al.
Page
of 8